Eli Lilly (LLY) is poised for potential growth as it prepares for the FDA’s decision on its oral weight loss drug, orforglipron, expected on April 10. The pharmaceutical giant has already seen significant success with its injectable weight loss products, Mounjaro and Zepbound, which have generated over $11 billion in revenue, showcasing triple-digit growth. This surge in demand highlights a growing market for weight loss treatments, particularly as Lilly captures 60% of the U.S. market.
The upcoming approval could further enhance Lilly’s position in the lucrative weight loss sector, which analysts predict could reach nearly $100 billion by the end of the decade. Orforglipron’s convenience as an oral medication may attract more patients compared to competitors, potentially leading to higher margins for Lilly as well.
Investors may find this a strategic entry point, given the stock’s recent dip and attractive valuation. Whether buying now or post-approval, Lilly presents a compelling long-term investment opportunity in the expanding weight loss drug market.
Source: fool.com